Prophylactic treatment with alkaline phosphatase in cardiac surgery induces endogenous alkaline phosphatase release

• Published in: International journal of artificial organs Vol. 35; no. 2; p. 144
• Main Authors: Kats, Suzanne, Brands, Ruud, Hamad, Mohamed A Soliman, Seinen, Willem, Scharnhorst, Volkher, Wulkan, Raymond W, Schönberger, Jacques P, Oeveren, Wim van
• Format: Journal Article
• Language: English
• Published: United States 01.02.2012
• Subjects: Aged; Alkaline Phosphatase - administration & dosage; Alkaline Phosphatase - blood; Cardiopulmonary Bypass - adverse effects; Coronary Artery Bypass - adverse effects; Double-Blind Method; Drug Administration Schedule; Female; Humans; Immunity, Innate; Inflammation - etiology; Inflammation - immunology; Inflammation - prevention & control; Infusions, Intravenous; Intestines - enzymology; Male; Middle Aged; Netherlands; Premedication; Prospective Studies; Time Factors; Treatment Outcome; Up-Regulation; Netherlands
• ISSN: 1724-6040
• DOI: 10.5301/ijao.5000039

Laboratory and clinical data have implicated endotoxin as an important factor in the inflammatory response to cardiopulmonary bypass. We assessed the effects of the administration of bovine intestinal alkaline phosphatase (bIAP), an endotoxin detoxifier, on alkaline phosphatase levels in patients undergoing coronary artery bypass grafting. A total of 63 patients undergoing coronary artery bypass grafting were enrolled and prospectively randomized. Bovine intestinal alkaline phosphatase (n=32) or placebo (n=31) was administered as an intravenous bolus followed by continuous infusion for 36 hours. The primary endpoint was to evaluate alkaline phosphatase levels in both groups and to find out if administration of bIAP to patients undergoing CABG would lead to endogenous alkaline phosphatase release. No significant adverse effects were identified in either group. In all the 32 patients of the bIAP-treated group, we found an initial rise of plasma alkaline phosphatase levels due to bolus administration (464.27±176.17 IU/L). A significant increase of plasma alkaline phosphatase at 4-6 hours postoperatively was observed (354.97±95.00 IU/L) as well. Using LHA inhibition, it was shown that this second peak was caused by the generation of tissue non specific alkaline phosphatase (TNSALP-type alkaline phosphatase). Intravenous bolus administration plus 8 hours continuous infusion of alkaline phosphatase in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass results in endogenous alkaline phosphatase release. This endogenous alkaline phosphatase may play a role in the immune defense system.